Red Light Holland Reports Positive Preclinical Study Results for Coca in Weight Gain Prevention Post GLP-1 from Magdalena Biosciences, the Joint Venture Held Through Its Wholly Owned Subsidiary, Filament Health

About this update from Red Light Holland Corp

Toronto, Ontario--(Newsfile Corp. - June 18, 2026) - Red Light Holland Corp. (CSE: TRIP) (FSE: 4YX) (OTCQB: TRUFF) ("Red Light Holland", "Red Light", or the "Company") is an Ontario based organization advancing innovation and research within the legal psychedelic sector. Following its acquisition of Filament Health Corp. ("Filament"), the Company has expanded its pharmaceutical grade manufacturing, regulatory, and clinical research capabilities, supporting the advancement of naturally derived drug development. Through the Filament acquisition, the Company also holds Filament's interest in Magdalena Biosciences, Inc. ("Magdalena"), a US based joint venture formed by Filament and Jaguar Health, Inc. (NASDAQ: JAGX) ("Jaguar"). The Company is pleased to report that Magdalena has announced positive results of a preclinical study demonstrating that a novel extract derived from the leaves of the coca plant prevented weight gain in mice placed on a high fat diet, without reducing food intake or increasing physical activity. The coca leaf extract under evaluation is Magdalena's prescription drug candidate for post-GLP-1 weight loss management, intended for development under the U.S. Food and Drug Administration's Botanical Guidance. It is common for people to regain weight after stopping GLP-1 medications, as these drugs help reduce appetite and increase feelings of fullness while they are being taken. When treatment is discontinued, those effects diminish, and the body's mechanisms that regulate hunger and body weight may promote weight gain. Magdalena's thesis is that the coca leaf extract under evaluation may have the potential to serve as a weight maintenance therapy following cessation of GLP-1 therapy, addressing a significant unmet need for safe, long term weight management solutions. The 20 day preclinical study was conducted in Alberta, Canada, in collaboration with the Borgland Lab at the University of Calgary, where Stephanie Borgland, PhD, served as Principal Investigator. The coca leaf used in the research and development program was provided to Magdalena by Empresa Nacional de La Coca (ENACO), a Peruvian state company dedicated to the commercialization of the coca leaf and its derivatives, under an Internationally Recognized Certificate of Compliance (IRCC) consistent wit...

View stock analysis, news, and events for Red Light Holland Corp